CanaQuest develops cannabinoid-based therapeutics, focusing on CQ-001, a cannabidiol-omega-3 formulation for refractory epilepsy, demonstrating 35% > potency and advancing epilepsy treatment innovation with a world-class team through to commercialization. Based on successful pre-clinical trial results, CanaQuest is planning to complete human trials and seek regulatory approval for Mentanine®Rx by
applying for a Drug Identification Number “DIN number” with the US-based Food and Drug Administration (FDA) and Health Canada. The Company believes the FDA and Health Canada approval process will be significantly reduced because of the quality of the pre-clinical work and the recent regulatory approvals which have been provided for other products containing CBD and THC. The company is also in discussions with a pharmaceutical company to formalize a collaboration, production, and a distribution agreement. Simultaneously, together with other potential pharma partners, the company is in the process of organizing Human Trials to prove the small dosage efficacy and safety data following randomized double-blind, placebo-controlled trials. Mentanine® (Omega3 compounds + CBD isolate - pharma-grade - highly bioavailable formulation) was produced and successfully tested for quality and safety by third-party laboratories in the USA and Canada. Results from pre-clinical trials addressing anxiety, depression, PTSD, and schizophrenia have been scientifically significant. These results also demonstrate a reduction of inflammation, which has beneficial implications for pain. Additionally, this can be used to decrease opioid addiction effects and schizophrenia-related symptoms. Mentanine® a scientifically developed and formulated medical product is tasteless and can be produced as a water-soluble liquid or powder, with substantially improved bioavailability. Dr. Laviolette (of Western University) stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other approved CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising anti-epilepsy treatment, which I believe makes the formulation even more promising for these applications.”
Mentanine® Pre-clinical trials:
1. Indicated 10 times + the efficacy as compared to CBD molecules alone
2. Reduced Anxiety, Depression, PTSD, and Addictive effects.
3. Showed significant reduction of inflammation, which can be beneficial for pain management. This formulation can be administrated with a significantly faster rate of absorption and significantly smaller doses compared to other CBD medications, therefore, reducing or even eliminating the negative side effects of liver toxicity caused by high consumption of CBD oils available today. Mentabinol® (THC + L-Theanine)
This medical cannabis formulation is a safer alternative to all other THC products, addressing anxiety, depression, and schizophrenia while protecting all THC users from negative psychiatric side-effects. The Company has applied to Health Canada and is waiting for approval to produce, sell, and export Mentabinol® under the Cannabis Act. Mentabinol® Pre-clinical trials:
1. Reversal of depression-like and schizophrenia-related symptoms
2. Complete blockage of memory impairment
3. Complete blockage of hyperactive activity
4. Complete blockage of gene vulnerability. CanaQuest’s wholly-owned subsidiary, ADC BioMedical Corp, was awarded a cannabis and cannabinoid products, Sales/Purchase, Import/Export license from Health Canada for Medical purposes. CanaQuest is launching Mentanine®, scientifically developed, soon, which will be available to patients, physicians, clinics, and Health Canada licensed entities. The Company is also positioned to launch Mentabinol® upon regulatory approval. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging have been selected to start production. As well, the Company is in discussions with several parties regarding domestic and international distribution.
